Comparative Pharmacology
Head-to-head clinical analysis: MIRAPEX versus ROPINIROLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRAPEX versus ROPINIROLE HYDROCHLORIDE.
MIRAPEX vs ROPINIROLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
Ropinirole is a non-ergoline dopamine agonist with high affinity for D2 and D3 dopamine receptors, particularly D3. It stimulates postsynaptic dopamine receptors in the striatum, compensating for dopamine deficiency in Parkinson's disease and modulating dopaminergic pathways in restless legs syndrome.
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
Initial: 0.25 mg orally three times daily; titrate weekly by increments of 0.25 mg three times daily up to 1 mg three times daily, then 0.5 mg three times daily up to 3 mg three times daily; maximum 8 mg three times daily (24 mg/day).
None Documented
None Documented
The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function.
Terminal elimination half-life: 5-6 hours in young healthy adults; 6-8 hours in elderly. Clinically, steady-state achieved within 2 days.
Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%).
Renal: 88% (primarily as metabolites, <10% unchanged). Fecal: <5%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist